The paper by Adams et al 1 on the pre-emptive use of aerosolized ribavirin in the treatment of asymptomatic pediatric marrow transplant patients testing positive for RSV deserves clarification and further scrutiny. Specifically, the performance of the RSV ELISA in the hands of the investigators and when applied to the study patients should be clarified. Clearly, if a substantial number of false positive test results occur then the benign clinical outcomes of these potentially misidentified patients would be the rule and would not be the result of the drug treatment employed. The authors state that the ELISA sensitivity is 81.7% and the specificity is 93.6%. This RSV ELISA assay was developed and characterized in symptomatic infants and children. However, the performance of the assay when applied to asymptomatic patients is the critical test characteristic for this study. It would be expected that the likelihood of false positives would increase when this test is applied to such an asymptomatic population. If, for example, the sensitivity and specificity of the ELISA as stated was around 90%, the predictive value of a positive test would only be 0.32 if the prior probability of true infection was 0.05. Since the ratio of positive to negative test results reported in this study was approximately 0.07, it seems possible that most or even all ELISA positive patients in this study could represent false positives. Unfortunately, no confirmatory cultures were performed and DFA back-up was only reportedly used in this study if the RSV ELISA was negative, therefore not addressing this potential problem of ELISA false positivity.
Response
We appreciate the opportunity to respond to Dr DeVincenzo's comments regarding the use of virologic testing for respiratory syncytial virus (RSV) and its effect on the preemptive use of antiviral therapy to prevent severe respiratory disease. We agree with Dr DeVincenzo that the current diagnostic technologies are not ideal. No existing virologic diagnostic tests have a sensitivity of 100%. Depending on the type of clinical specimen submitted, rapid diagnostic assays such as enzyme-linked immunoassay and direct fluorescent assays have sensitivities averaging approximately 80-90%. In many studies, specimens portion (as defined by culture identification) which we have observed at St Jude Children's Research Hospital (5/274 ϭ 1.8%) over a 4 year observation of successive marrow transplants. 3 There are additional lesser indications in the paper intimating false positive ELISA test results. Many patients were RSV ELISA positive only once during their transplant period. In addition, the authors report that a 5 day ribavirin treatment cleared the RSV infections in all but one patient. Given the anti-viral characteristics of ribavirin, it is unlikely that this 5 day treatment would have eradicated actual RSV infection in BMT patients. In addition, all patients except one (UUPN 337, the patient known to be RSV positive prior to transplant) tested negative only 48 and 72 h later, thus evoking the phenomenon of 'regression to the mean'.
In summary, the serious question of falsely identified RSV-infected study patients needs to be answered before the paper's conclusions can be accepted.
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obtained from children from nasopharyngeal aspirates and washes have a higher sensitivity than throat swab and endotracheal specimens. However in adults, endotracheal specimens appear to have a higher sensitivity. 1 The specificity from the various tests also vary, but generally are in the 90% or above range. 2 While cultures are considered by some to be the 'gold standard', unfortunately their sensitivity is low. In studies published by Michael et al 2 and Krilov et al,
